CKD Stage 3: An Individual Diet and Monitoring Plan

CKD stage 3 spans G3a (eGFR ≥45 and <60) and G3b (≥30 and <45). An eGFR below 60 lasting at least three months is one criterion for chronic kidney disease; a new result requires assessment of chronicity and possible acute causes. Many people in this range have no symptoms.

Stage 3 does not define one diet, one blood pressure target, or one testing schedule. Urine albumin, the cause and trend, nutritional status, other illnesses, and prescribed treatments change the plan.

Start with the information that changes decisions

Fatigue, swelling, or urination changes can have several causes. They are not a way to diagnose stage 3. New marked symptoms or a sudden fall should be evaluated rather than attributed to a chronic stage label.

Protein: avoid an automatic low-protein diet

KDIGO 2024 suggests about 0.8 g/kg/day of protein for adults with CKD G3–G5. This is guidance to individualize, not a prescription from a calculator. Frailty, muscle loss, undernutrition, growth, acute illness, and dialysis can change needs. More restrictive diets require appropriate supervision and may be unsuitable.

A renal dietitian can consider protein sources, adequate energy intake, appetite, and body composition. Do not apply an adult weight-based protein target to a child or assume everyone with G3b should reduce protein further.

Sodium, potassium, phosphorus and fluids

Reducing heavily salted processed foods often helps blood pressure and swelling. KDIGO suggests less than 2 g of sodium daily for people with CKD, with exceptions such as sodium-wasting conditions. Sodium is not the same as salt: 2 g sodium is roughly 5 g salt.

The NIDDK kidney nutrition guide emphasizes that nutrient and fluid needs change. Potassium and phosphorus restrictions should follow laboratory results and individual assessment, rather than a blanket ban on fruit, vegetables, legumes, or dairy. Portion size and additives matter. Potassium-containing salt substitutes may be inappropriate when potassium is high.

Do not force extra water to improve eGFR. Fluid advice depends on urine output, swelling, medicines, heart function, and the clinical plan.

Treatment is broader than diet

Blood pressure control, diabetes management when relevant, selected kidney-protective medicines, cardiovascular risk reduction, smoking cessation, and appropriate activity may be part of care. Eligibility for medicines such as ACE inhibitors, ARBs or SGLT2 inhibitors depends on the person's condition and monitoring needs.

A blood pressure target is individualized. KDIGO's systolic target below 120 for selected adults with high blood pressure and CKD depends on standardized office measurement and tolerability; it is not a universal home “120/80” rule. Frailty, falls, postural symptoms, and other factors may change goals.

Set the testing schedule with the care team

Monitoring frequency depends on GFR category, albuminuria, rate of change, complications, and treatment changes. A fixed schedule based only on “stage 3a” or “stage 3b” misses those differences. Kidney function and albuminuria should be checked at least annually in CKD, with more frequent assessment when risk is higher or results could affect treatment.

Ask which tests are needed and when, what change should trigger earlier contact, whether nephrology input is appropriate, and how to follow the plan during illness. Referral may relate to rapid decline, substantial albuminuria, uncertain cause, resistant hypertension, complications, or kidney-failure risk rather than the stage label alone.

Keep a dated log of laboratory values, blood pressure and medication changes. The age and CKD guide explains why age averages do not override diagnosis. The medication guide explains why stages do not select drug doses.